Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 90

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 90
---
 the A&R 2011 Plan. • No liberal change in control definition. Change in control benefits are triggered only by the occurrence, rather than stockholder approval, of a merger or other change in control event. • Minimum vesting requirements. Awards are subject to a minimum vesting period of one year from the date of grant, except for a 5% allowable “carve-out” pool of shares authorized under the A&R 2011 Plan and except that our board may permit acceleration of vesting in the event of a recipient’s death, disability or retirement or a reorganization event. The A&R 2011 Plan includes a corresponding increase to the “carve-out pool”, from 987,726 shares to 1,112,727 shares, which equals 5% of the new number of shares authorized. • Dividend equivalent restrictions. Dividend equivalents may not be granted in tandem with, linked to, contingent upon or otherwise payable on the exercise of, any option or SAR, and if dividends are declared during the period that an award is outstanding, any applicable dividend equivalents will remain subject to performance and/or vesting requirement(s) to the same extent as the applicable award and will be paid only at the time or times such performance and/or vesting requirement(s) are satisfied.

Pacira BioSciences, Inc. 2025 Proxy Statement | 97

TABLE OF CONTENTS Executive Compensation

Information Regarding Additional Shares Requested As of April 1, 2025, there were 5,585,165 shares of common stock subject to outstanding awards and 9,882,095 shares of common stock reserved for future grants remaining under the 2011 Plan, representing 21.4% of our shares of common stock outstanding and 17.1% of our fully diluted shares of common stock outstanding (assuming the exercise and vesting, as applicable, of all outstanding equity awards, including the Amended and Restated 2014 Inducement Plan, and excluding any shares of common stock that may be issued to settle the conversion premium upon conversion of our convertible senior notes). Assuming adoption of the A&R 2011 Plan, shares of common stock subject to outstanding awards and shares of common stock reserved for future grants remaining under the A&R 2011 Plan (including the 2,500,000 newly reserved shares) would represent 27.6% of our shares of common stock outstanding and 22.0% of our fully diluted shares of common stock outstanding (assuming the exercise of all outstanding